To rapidly identify a human monoclonal antibody that potently neutralizes SARS-CoV-2 and that is suitable for clinical development for prevention and treatment of COVID-19 based on convalescent serum screening.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Davide F RobbianiResearch Location
United States of AmericaLead Research Institution
The Rockefeller UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
To rapidly identify a human monoclonal antibody that potently neutralizes SARS-CoV-2 and that is suitable for clinical development for prevention and treatment of COVID-19 based on convalescent serum screening.